Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil

Respiratory Physiology and Neurobiology

Volumn 186, Issue 1, 2013, Pages 61-64

  Schroll, Stephan ^a   Sebah, Daniela ^a   Wagner, Michael ^a   Popara, Viktoria ^a   Pfeifer, Michael ^a,b   Blumberg, Friedrich ^a,c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Donaustauf Hospital   (Germany)

^c PROSPER HOSPITAL   (Germany)

Author keywords

Exercise capacity; Monocrotaline; Pulmonary hypertension; Vardenafil

Indexed keywords

MONOCROTALINE; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; HEART RIGHT VENTRICLE PRESSURE; HEART WEIGHT; HEMODYNAMICS; LUNG BLOOD VESSEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREADMILL;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; IMIDAZOLES; MALE; MONOCROTALINE; PHOSPHODIESTERASE 5 INHIBITORS; PHYSICAL CONDITIONING, ANIMAL; PIPERAZINES; RATS; RATS, WISTAR; SULFONES; TRIAZINES;

EID: 84873106829     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2012.11.003     Document Type: Article

References (22)

1. Buckley M.S., Staib R.L., Wicks L.M., Feldman J.P. Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. Journal of Drug, Healthcare and Patient Safety 2010, 2:151-161.
2. Corbin J.D., Beasley A., Blount M.A., Francis S.H. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochemical and Biophysical Research Communications 2005, 334:930.
3. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., Shapiro S., White R.J., Chan M., Beardsworth A., Frumkin L., Barst R.J. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
4. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 2005, 353:2148-2157.
5. Geiger R., Treml B., Kleinsasser A., Neu N., Fischer V., Stein J.I., Loeckinger A. Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hypertension. High Altitude Medicine and Biology 2008, 9:223-227.
6. Ghofrani H.A., Voswinckel R., Reichenberger F., Olschewski H., Haredza P., Karadas B., Schermuly R.T., Weissmann N., Seeger W., Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Journal of the American College of Cardiology 2004, 44:1488.
7. Jing Z.C., Jiang X., Wu B.X., Xu X.Q., Wu Y., Ma C.R., Wang Y., Yang Y.J., Pu J.L., Gao W. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 2009, 95:1531-1536.
8. Jing Z.C., Yu Z.X., Shen J.Y., Wu B.X., Xu K.F., Zhu X.Y., Pan L., Zhang Z.L., Liu X.Q., Zhang Y.S., Jiang X., Galie N. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 2011, 183:1723-1729.
9. Langleben D., Brock T., Dixon R., Barst R. STRIDE 1: effects of the selective ET(A) receptor antagonist sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. Journal of Cardiovascular Pharmacology 2004, 44(Suppl. 1):S80-S84.
10. Lee D.S., Kim Y.K., Jung Y.W. Simvastatin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension. Korean Circulation Journal 2010, 40:659-664.
11. Maclean M.R., Johnston E.D., McCulloch K.M., Pooley L., Houslay M.D., Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. Journal of Pharmacology and Experimental Therapeutics 1997, 283:619-624.
12. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. New England Journal of Medicine 1993, 329:2002-2012.
13. Rondelet B., Kerbaul F., Van Beneden R., Motte S., Fesler P., Hubloue I., Remmelink M., Brimioulle S., Salmon I., Ketelslegers J.M., Naeije R. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 2004, 110:2220-2225.
14. Rosen R.C., Kostis J.B. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. American Journal of Cardiology 2003, 92:9M-18M.
15. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine 2002, 346:896-903.
16. Sawamura F., Kato M., Fujita K., Nakazawa T., Beardsworth A. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. Journal of Pharmacological Sciences 2009, 111:235-243.
17. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., Sydykov A., Lai Y.J., Weissmann N., Seeger W., Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation 2005, 115:2811-2821.
18. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Yilmaz H., Butrous G., Ermert L., Ermert M., Weissmann N., Rose F., Guenther A., Walmrath D., Seeger W., Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. American Journal of Respiratory and Critical Care Medicine 2004, 169:39-45.
19. Toque H.A., Teixeira C.E., Priviero F.B., Morganti R.P., Antunes E., De Nucci G. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. British Journal of Pharmacology 2008, 154:787-796.
20. Tsai B.M., Turrentine M.W., Sheridan B.C., Wang M., Fiore A.C., Brown J.W., Meldrum D.R. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. The Annals of Thoracic Surgery 2006, 81:272.
21. Wharton J., Strange J.W., Moller G.M.O., Growcott E.J., Ren X., Franklyn A.P., Phillips S.C., Wilkins M.R. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. American Journal of Respiratory and Critical Care Medicine 2005, 172:105-113.
22. Yen C.H., Leu S., Lin Y.C., Kao Y.H., Chang L.T., Chua S., Fu M., Wu C.J., Sun C.K., Yip H.K. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. Journal of Cardiovascular Pharmacology 2010, 55:574-584.